Certolizumab (CIMZIA) Neutralizing Antibody ELISA Assay Kit

$2,120.00

The Certolizumab (CIMZIA) Neutralizing Antibody ELISA Assay Kit is intended for the detection of neutralizing antibodies to certolizumab in serum and plasma samples. The Certolizumab (CIMZIA) Neutralizing Antibody ELISA Assay Kit is for research use only and not to be used for diagnostic procedures.

SKU: CER-TCAP-Nab-CIM Categories: , ,

Certolizumab (CIMZIA) Neutralizing Antibody ELISA Assay Kit

The Certolizumab (CIMZIA) Neutralizing Antibody ELISA Assay Kit is For Research Use Only

Size: 12 x 8 wells
Sensitivity: +/-
Incubation Time: 2 hours 20 minutes
Sample Type: Serum, Plasma
Sample Size: 10 µL
Alternative Name: Cimzia

Controls Included


Assay Background

Biological therapeutic proteins can induce the production of anti-drug antibodies (ADA), including neutralizing antibodies (NAb), and consequently result in unwanted immune response in recipients. NAb can diminish therapeutic efficacy by either preventing the drug from binding to its target or inhibiting downstream signaling upon binding due to steric hindrance. NAb can also cross-react and neutralize the biological activity of an endogenous counterpart in some cases, resulting in the impairment of an essential normal physiological function and life-threatening adverse effects. Therefore, it is essential to monitor the potential NAb during biological drug development. NAb monitoring provides the key information that could allow interpretation of safety studies. Non-neutralizing antibodies (non-NAb) are ADA that bind to sites on the drug molecule that do not affect target binding and there by do not impact the drug’s pharmacodynamic activity. Non-NAb are often referred to as ‘binding antibodies’, but that is an incorrect term because all types of ADA, are inherently binding antibodies since they bind drug as neutralizing antibodies. Neutralizing antibodies (NAb) are a subset of binding ADA that bind to the drug and inhibit its pharmacological function by preventing target binding. NAbs can inhibit drug activity soon after the drug is administered, but non-NAb do not inhibit the pharmacodynamic activity of the drug. A neutralizing antibody assay is based on neutralizing antibodies’ drug-target interaction blocking ability. As the concentration of NAb and/or NAb’s binding affinity to drug gets higher, drug-target binding interaction gets lower. In Target Capture Competitive Ligand Binding NAb assays’ design relies on the NAb and target’s competition to bind to the drug between each other. NAb assays are named as direct binding when the presence of NAb can be detected by reduction in signal.

Assay Principle

Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtiter plate coated with the drug Certolizumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to Certolizumab antibodies captured by the drug Certolizumab on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of Certolizumab antibodies in the sample or standard. Results of samples can be determined directly using the standard curve.


Related Products

Certolizumab (CIMZIA) ELISA Assay Kit
Anti-Certolizumab (CIMZIA) Quantitative ELISA Assay Kit

Documents

Product Manual


Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations